Diadema Partners »

Enliven Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $9.6k 245 39.20

More positions owned by Diadema Partners

United Therapeutics Corporation Put Option (UTHR)
Vertex Pharmaceuticals Incorporated (VRTX)
Viking Therapeutics (VKTX)
Capricor Therapeutics Com New Call Option (CAPR)
Abivax Sa Sponsored Ads (ABVX)
Liquidia Corporation Com New Call Option (LQDA)
Revolution Medicines (RVMD)
Apogee Therapeutics Call Option (APGE)
Bridgebio Pharma Note 1.750% 3/0
Incyte Corporation Put Option (INCY)
Kodiak Sciences Put Option (KOD)
Cytokinetics Com New Call Option (CYTK)
Johnson & Johnson (JNJ)
Cogent Biosciences (COGT)
Merck & Co Put Option (MRK)

View all positions for Diadema Partners

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Polar Capital Holdings
BlackRock
Commodore Capital
Vestal Point Capital
Bellevue Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
Pictet Asset Management Holding SA
State Street Corporation
Geode Capital Management
Logos Global Management

View all funds holding Enliven Therapeutics